Russia's Gamaleya National Research Centre of Epidemiology and Microbiology is developing a medicine containing antibodies to treat coronavirus patients, the centre's director, Alexander Gintsburg, said.
"We are currently developing antibodies that can be given to patients with coronavirus in the form of a medicine," Sputnik cited Gintsburg as saying.
"We will start clinical trials in January next year, and I hope that we will complete these clinical trials within three to four months", he added.
Concerning the issue of using a nasal vaccine against the new coronavirus infection instead of ordinary vaccination, Gintsburg said that it will be decided during clinical trials, and there is no definite answer yet.
"The question is good, correct, there is no unequivocal answer to this. During the clinical trials for which we have received permission, one of the questions that will be resolved... will be the one that you have now asked me", Gintsburg said when asked whether the nasal vaccine against COVID-19 could replace an injection or will be used as a supplement to it, for example, during revaccination.
